Journal of veterinary pharmacology and therapeutics2004; 27(6); 479-490; doi: 10.1111/j.1365-2885.2004.00617.x

Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest.

Abstract: This review summarises selected aspects of the pharmacokinetics (PK) and pharmacodynamics (PD) of nonsteroidal anti-inflammatory drugs (NSAIDs). It is not intended to be comprehensive, in that it covers neither minor species nor several important aspects of NSAID PD. The limited objective of the review is to summarise those aspects of NSAID PK and PD, which are important to an understanding of PK-PD integration and PK-PD modelling (the subject of the next review in this issue). The general features of NSAID PK are: usually good bioavailability from oral, intramuscular and subcutaneous administration routes (but with delayed absorption in horses and ruminants after oral dosing), a high degree of binding to plasma protein, low volumes of distribution, limited excretion of administered dose as parent drug in urine, marked inter-species differences in clearance and elimination half-life and ready penetration into and slow clearance from acute inflammatory exudate. The therapeutic effects of NSAIDs are exerted both locally (at peripheral inflammatory sites) and centrally. There is widespread acceptance that the principal mechanism of action (both PD and toxicodynamics) of NSAIDs at the molecular level comprises inhibition of cyclooxygenase (COX), an enzyme in the arachidonic acid cascade, which generates inflammatory mediators of the prostaglandin group. However, NSAIDs possess also many other actions at the molecular level. Two isoforms of COX have been identified. Inhibition of COX-1 is likely to account for most of the side-effects of NSAIDs (gastrointestinal irritation, renotoxicity and inhibition of blood clotting) but a minor contribution also to some of the therapeutic effects (analgesic and anti-inflammatory actions) cannot be excluded. Inhibition of COX-2 accounts for most and possibly all of the therapeutic effects of NSAIDs. Consequently, there has been an intensive search to identify and develop drugs with selectivity for inhibition of COX-2. Whole blood in vitro assays are used to investigate quantitatively the three key PD parameters (efficacy, potency and sensitivity) for NSAID inhibition of COX isoforms, providing data on COX-1:COX-2 inhibition ratios. Limited published data point to species differences in NSAID-induced COX inhibition, for both potency and potency ratios. Members of the 2-arylpropionate sub-groups of NSAIDs exist in two enantiomeric forms [R-(-) and S-(+)] and are licensed as racemic mixtures. For these drugs there are marked enantiomeric differences in PK and PD properties of individual drugs in a given species, as well as important species differences in both PK and PD properties.
Publication Date: 2004-12-17 PubMed ID: 15601442DOI: 10.1111/j.1365-2885.2004.00617.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research paper is a review that summarises the pharmacokinetics and pharmacodynamics aspects of nonsteroidal anti-inflammatory drugs (NSAIDs) in veterinary species, highlighting the general features of their absorption, action mechanisms, effects, and inter-species differences.

Pharmacokinetics of NSAIDs

This part of the review discusses the movement of NSAIDs within the body of different animal species. Key aspects included are:

  • Good bioavailability: These drugs can effectively enter the body’s system from oral, intramuscular and subcutaneous administration routes, although the absorption rate is delayed in horses and ruminants after oral dosing.
  • High degree of binding to plasma protein: means that a large proportion of the anti-inflammatory drugs have the ability to combine with proteins within the blood.
  • Low volumes of distribution: The NSAIDs do not spread widely within the body.
  • Limited excretion as parent drug: A small percentage of administered NSAIDs are excreted from the body without being metabolised.
  • Inter-species differences: The rates of clearance and elimination half-life of NSAIDs vary between different animal species.

Pharmacodynamics of NSAIDs

The paper further explores how NSAIDs affect the bodies of different animal species.

  • Mode of action: NSAIDs inhibit cyclooxygenase (COX), an enzyme that catalyses the production of prostaglandins which are mediators of inflammation. Besides, they also display other various actions at the molecular level.
  • Impact of COX inhibition: The inhibition of COX-1, one of the COX’s isoforms, primarily results in side effects such as gastrointestinal irritation, kidney toxicity and inhibition of blood clotting. Yet, it also contributes to some beneficial therapeutic effects. On the other hand, inhibiting COX-2, the other isoform, accounts for most, if not all, of the therapeutic effects of NSAIDs.
  • Differences across species: There are differences in NSAID-induced COX inhibition in terms of effectiveness and potency ratios across different species.

Focus on 2-arylpropionate family of NSAIDs

Special attention is given to the 2-arylpropionate subtype of NSAIDs that exists in two forms – R-(-) and S-(+).

  • PK and PD differences: There are species-specific differences and enantiomeric, or structural, differences in how the body processes these drugs (pharmacokinetics) and how they affect the body (pharmacodynamics).

Cite This Article

APA
Lees P, Landoni MF, Giraudel J, Toutain PL. (2004). Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. J Vet Pharmacol Ther, 27(6), 479-490. https://doi.org/10.1111/j.1365-2885.2004.00617.x

Publication

ISSN: 0140-7783
NlmUniqueID: 7910920
Country: England
Language: English
Volume: 27
Issue: 6
Pages: 479-490

Researcher Affiliations

Lees, P
  • Royal Veterinary College, Hawkshead Campus, Hatfield, Hertfordshire AL9 7TA, UK. plees@rvc.ac.uk
Landoni, M F
    Giraudel, J
      Toutain, P L

        MeSH Terms

        • Animals
        • Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics
        • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
        • Cyclooxygenase Inhibitors / pharmacokinetics
        • Cyclooxygenase Inhibitors / pharmacology
        • Humans
        • Inhibitory Concentration 50
        • Models, Animal
        • Models, Biological
        • Species Specificity
        • Veterinary Drugs / pharmacokinetics
        • Veterinary Drugs / pharmacology

        Citations

        This article has been cited 46 times.
        1. Sarvi JY, Gardhouse SM, Kleinhenz MD, Hocker SE, Weeder MM, Montgomery SR, Rooney TA. Measurement of Cyclooxygenase Products in Plasma as Markers for Inhibition of Cyclooxygenase Isoforms by Oral Meloxicam in New Zealand White Rabbits (Oryctolagus cuniculus ).. J Am Assoc Lab Anim Sci 2023 May 1;62(3):254-259.
        2. Fadel C, Giorgi M. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses.. Vet Anim Sci 2023 Mar;19:100286.
          doi: 10.1016/j.vas.2023.100286pubmed: 36684818google scholar: lookup
        3. Tou K, Cawley A, Bowen C, Bishop DP, Fu S. Towards Non-Targeted Screening of Lipid Biomarkers for Improved Equine Anti-Doping.. Molecules 2022 Dec 30;28(1).
          doi: 10.3390/molecules28010312pubmed: 36615506google scholar: lookup
        4. Almeida ZL, Brito RMM. Amyloid Disassembly: What Can We Learn from Chaperones?. Biomedicines 2022 Dec 17;10(12).
          doi: 10.3390/biomedicines10123276pubmed: 36552032google scholar: lookup
        5. Flood J, Stewart AJ. Non-Steroidal Anti-Inflammatory Drugs and Associated Toxicities in Horses.. Animals (Basel) 2022 Oct 26;12(21).
          doi: 10.3390/ani12212939pubmed: 36359062google scholar: lookup
        6. Fadel C, u0141ebkowska-Wieruszewska B, Sartini I, Lisowski A, Poapolathep A, Giorgi M. Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration.. J Vet Pharmacol Ther 2022 Nov;45(6):550-557.
          doi: 10.1111/jvp.13089pubmed: 35899473google scholar: lookup
        7. Nixon E, Chittenden JT, Baynes RE, Messenger KM. Pharmacokinetic/pharmacodynamic modeling of ketoprofen and flunixin at piglet castration and tail-docking.. J Vet Pharmacol Ther 2022 Sep;45(5):450-466.
          doi: 10.1111/jvp.13083pubmed: 35833463google scholar: lookup
        8. Enouri SS, O'Sullivan TL, Ramkissoon S, Friendship RM, Gu Y, Johnson RJ. Pharmacokinetics of combined administration of iron dextran with meloxicam or flunixin meglumine in piglets.. Can Vet J 2022 Jul;63(7):727-734.
          pubmed: 35784780
        9. Gu00f3mez-Segura L, Boix-Montau00f1es A, Mallandrich M, Parra-Coca A, Soriano-Ruiz JL, Calpena AC, Gimeno u00c1, Bellido D, Colom H. Swine as the Animal Model for Testing New Formulations of Anti-Inflammatory Drugs: Carprofen Pharmacokinetics and Bioavailability of the Intramuscular Route.. Pharmaceutics 2022 May 12;14(5).
          doi: 10.3390/pharmaceutics14051045pubmed: 35631631google scholar: lookup
        10. Moru00f3n-Elorza P, Cau00f1izares-Cooz D, Rojo-Solis C, u00c1lvaro-u00c1lvarez T, Valls-Torres M, Garcu00eda-Pu00e1rraga D, Encinas T. Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (Raja undulata).. Vet Sci 2022 Apr 28;9(5).
          doi: 10.3390/vetsci9050216pubmed: 35622744google scholar: lookup
        11. Lees P, Toutain PL, Elliott J, Giraudel JM, Pelligand L, King JN. Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib.. J Vet Pharmacol Ther 2022 Jul;45(4):325-351.
          doi: 10.1111/jvp.13052pubmed: 35460083google scholar: lookup
        12. Moru00f3n-Elorza P, Rojo-Solu00eds C, u00c1lvaro-u00c1lvarez T, Valls-Torres M, Garcu00eda-Pu00e1rraga D, Encinas T. Pharmacokinetic Studies in Elasmobranchs: Meloxicam Administered at 0.5 mg/kg Using Intravenous, Intramuscular, and Oral Routes to Nusehound Sharks (Scyliorhinus stellaris).. Front Vet Sci 2022;9:845555.
          doi: 10.3389/fvets.2022.845555pubmed: 35411304google scholar: lookup
        13. Mainau E, Llonch P, Temple D, Goby L, Manteca X. Alteration in Activity Patterns of Cows as a Result of Pain Due to Health Conditions.. Animals (Basel) 2022 Jan 12;12(2).
          doi: 10.3390/ani12020176pubmed: 35049798google scholar: lookup
        14. Reynolds KJ, Johnson R, Friendship RM, Brown J, Enouri S, Gehring R, O'Sullivan TL. Pharmacokinetics and bioavailability of ketoprofen when compounded with iron dextran for use in nursing piglets.. Can Vet J 2021 Nov;62(11):1211-1218.
          pubmed: 34728849
        15. Plummer C, White PJ, Kimble B, Govendir M, Van der Saag D. Preliminary Investigation into a Novel Sustained-Release Formulation of Meloxicam in Sheep (Ovis aries)-Pharmacokinetic Profile.. Animals (Basel) 2021 Aug 24;11(9).
          doi: 10.3390/ani11092484pubmed: 34573450google scholar: lookup
        16. Fazzio LE, Raggio SJ, Romero JF, Membrebe J, Minervino AHH. Safety Study on Ketoprofen in Pigs: Evaluating the Effects of Different Dosing and Treatment Scheme on Hematological, Hepatic, and Renal Parameters.. Vet Sci 2021 Feb 18;8(2).
          doi: 10.3390/vetsci8020030pubmed: 33670460google scholar: lookup
        17. Gu00f3mez-Segura L, Parra A, Calpena AC, Gimeno u00c1, Boix-Montau00f1es A. Carprofen Permeation Test through Porcine Ex Vivo Mucous Membranes and Ophthalmic Tissues for Tolerability Assessments: Validation and Histological Study.. Vet Sci 2020 Oct 10;7(4).
          doi: 10.3390/vetsci7040152pubmed: 33050372google scholar: lookup
        18. Trimboli F, Ragusa M, Piras C, Lopreiato V, Britti D. Outcomes from Experimental Testing of Nonsteroidal Anti-Inflammatory Drug (NSAID) Administration during the Transition Period of Dairy Cows.. Animals (Basel) 2020 Oct 8;10(10).
          doi: 10.3390/ani10101832pubmed: 33050071google scholar: lookup
        19. Knych HK, Finno CJ, Baden R, Arthur RM, McKemie DS. Identification and characterization of the enzymes responsible for the metabolism of the non-steroidal anti-inflammatory drugs, flunixin meglumine and phenylbutazone, in horses.. J Vet Pharmacol Ther 2021 Jan;44(1):36-46.
          doi: 10.1111/jvp.12891pubmed: 32757313google scholar: lookup
        20. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective.. Biochem Pharmacol 2020 Oct;180:114147.
          doi: 10.1016/j.bcp.2020.114147pubmed: 32653589google scholar: lookup
        21. Nixon E, Almond GW, Baynes RE, Messenger KM. Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets.. Front Vet Sci 2020;7:82.
          doi: 10.3389/fvets.2020.00082pubmed: 32154277google scholar: lookup
        22. Gu00f3mez-Segura L, Parra A, Calpena-Campmany AC, Gimeno u00c1, Gu00f3mez de Aranda I, Boix-Montau00f1es A. Ex Vivo Permeation of Carprofen Vehiculated by PLGA Nanoparticles through Porcine Mucous Membranes and Ophthalmic Tissues.. Nanomaterials (Basel) 2020 Feb 18;10(2).
          doi: 10.3390/nano10020355pubmed: 32085577google scholar: lookup
        23. DeMarco GJ, Nunamaker EA. A Review of the Effects of Pain and Analgesia on Immune System Function and Inflammation: Relevance for Preclinical Studies.. Comp Med 2019 Dec 1;69(6):520-534.
          doi: 10.30802/AALAS-CM-19-000041pubmed: 31896389google scholar: lookup
        24. Foley PL, Kendall LV, Turner PV. Clinical Management of Pain in Rodents.. Comp Med 2019 Dec 1;69(6):468-489.
          doi: 10.30802/AALAS-CM-19-000048pubmed: 31822323google scholar: lookup
        25. Vidotto VT, da Rocha RT, de Paiva CL, Nardotto JR, Farias A, Stefanes SA. Comparative Study of the Use of Intra-articular and Systemic Meloxicam to Control Experimentally Induced Osteoarthritis in Rabbit Knees.. Rev Bras Ortop 2013 Nov-Dec;48(6):524-531.
          doi: 10.1016/j.rboe.2013.12.011pubmed: 31304164google scholar: lookup
        26. Melu00e9ndez DM, Marti S, Pajor EA, Sidhu PK, Gellatly D, Janzen ED, Schwinghamer TD, Coetzee JF, Schwartzkopf-Genswein KS. Pharmacokinetics of oral and subcutaneous meloxicam: Effect on indicators of pain and inflammation after knife castration in weaned beef calves.. PLoS One 2019;14(5):e0217518.
          doi: 10.1371/journal.pone.0217518pubmed: 31125384google scholar: lookup
        27. Woodland AN, Van der Saag D, Kimble B, White PJ, Govendir M, Lomax S. Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep.. PLoS One 2019;14(4):e0215842.
          doi: 10.1371/journal.pone.0215842pubmed: 31017959google scholar: lookup
        28. Mendoza FJ, Serrano-Rodriguez JM, Perez-Ecija A. Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses.. J Vet Intern Med 2019 Mar;33(2):961-967.
          doi: 10.1111/jvim.15433pubmed: 30768821google scholar: lookup
        29. Melu00e9ndez DM, Marti S, Pajor EA, Moya D, Gellatly D, Janzen ED, Schwartzkopf-Genswein KS. Effect of subcutaneous meloxicam on indicators of acute pain and distress after castration and branding in 2-mo-old beef calves1,2.. J Anim Sci 2018 Sep 7;96(9):3606-3621.
          doi: 10.1093/jas/sky245pubmed: 29912457google scholar: lookup
        30. Worboys M, Toon E. Phenylbutazone (Bute, PBZ, EPZ): one drug across two species.. Hist Philos Life Sci 2018 Mar 26;40(2):27.
          doi: 10.1007/s40656-018-0191-4pubmed: 29582183google scholar: lookup
        31. Oliver VL, Thurston SE, Lofgren JL. Using Cageside Measures to Evaluate Analgesic Efficacy in Mice (Mus musculus) after Surgery.. J Am Assoc Lab Anim Sci 2018 Mar 1;57(2):186-201.
          pubmed: 29555008
        32. Cagnardi P, Guccione J, Villa R, D'Andrea L, Di Loria A, Ferrante MC, Borriello G, Zicarelli L, Ciaramella P. Clinical efficacy and pharmacokinetics of meloxicam in Mediterranean buffalo calves (Bubalus bubalis).. PLoS One 2017;12(10):e0187252.
          doi: 10.1371/journal.pone.0187252pubmed: 29077759google scholar: lookup
        33. Dhondt L, Devreese M, Croubels S, De Baere S, Haesendonck R, Goessens T, Gehring R, De Backer P, Antonissen G. Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus).. Sci Rep 2017 Sep 25;7(1):12043.
          doi: 10.1038/s41598-017-12159-zpubmed: 28947805google scholar: lookup
        34. Pelligand L, Soubret A, King JN, Elliott J, Mochel JP. Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats.. CPT Pharmacometrics Syst Pharmacol 2016 Nov;5(11):625-635.
          doi: 10.1002/psp4.12141pubmed: 27770596google scholar: lookup
        35. Espu00edn S, Garcu00eda-Fernu00e1ndez AJ, Herzke D, Shore RF, van Hattum B, Martu00ednez-Lu00f3pez E, Coeurdassier M, Eulaers I, Fritsch C, Gu00f3mez-Ramu00edrez P, Jaspers VL, Krone O, Duke G, Helander B, Mateo R, Movalli P, Sonne C, van den Brink NW. Tracking pan-continental trends in environmental contaminationu00a0using sentinel raptors-what types of samples should we use?. Ecotoxicology 2016 May;25(4):777-801.
          doi: 10.1007/s10646-016-1636-8pubmed: 26944290google scholar: lookup
        36. Karademir U, Aksit D, Kum C, Erdogan H, Ucar EH, Peker C, Gokbulut C. The effect of surgery (Ovariohysterectomy) on the plasma disposition of meloxicam following intravenous administration in dogs.. BMC Vet Res 2016 Feb 20;12:33.
          doi: 10.1186/s12917-016-0659-ypubmed: 26896943google scholar: lookup
        37. Culp WT, Weisse C, Berent AC, Reetz JA, Krick EL, Jackson DE, Kass PH, Clifford CA, Sorenmo KU. Early tumor response to intraarterial or intravenous administration of carboplatin to treat naturally occurring lower urinary tract carcinoma in dogs.. J Vet Intern Med 2015 May-Jun;29(3):900-7.
          doi: 10.1111/jvim.12594pubmed: 25900646google scholar: lookup
        38. Newby NC, Renaud D, Tremblay R, Duffield TF. Evaluation of the effects of treating dairy cows with meloxicam at calving on retained fetal membranes risk.. Can Vet J 2014 Dec;55(12):1196-9.
          pubmed: 25477550
        39. Kendall LV, Hansen RJ, Dorsey K, Kang S, Lunghofer PJ, Gustafson DL. Pharmacokinetics of sustained-release analgesics in mice.. J Am Assoc Lab Anim Sci 2014 Sep;53(5):478-84.
          pubmed: 25255070
        40. Jeunesse EC, Schneider M, Woehrle F, Faucher M, Lefebvre HP, Toutain PL. Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog.. BMC Vet Res 2013 Dec 11;9:250.
          doi: 10.1186/1746-6148-9-250pubmed: 24330630google scholar: lookup
        41. Tummaruk P, Sang-Gassanee K. Effect of farrowing duration, parity number and the type of anti-inflammatory drug on postparturient disorders in sows: a clinical study.. Trop Anim Health Prod 2013 Apr;45(4):1071-7.
          doi: 10.1007/s11250-012-0315-xpubmed: 23143739google scholar: lookup
        42. Strait KR, Orkin JL, Anderson DC, Muly EC. Chronic, constant-rate, gastric drug infusion in nontethered rhesus macaques (Macaca mulatta).. J Am Assoc Lab Anim Sci 2010 Mar;49(2):207-14.
          pubmed: 20353697
        43. Pacharinsak C, Beitz A. Animal models of cancer pain.. Comp Med 2008 Jun;58(3):220-33.
          pubmed: 18589864
        44. Steagall PV, Mantovani FB, Ferreira TH, Salcedo ES, Moutinho FQ, Luna SP. Evaluation of the adverse effects of oral firocoxib in healthy dogs.. J Vet Pharmacol Ther 2007 Jun;30(3):218-23.
        45. Cuthbert R, Parry-Jones J, Green RE, Pain DJ. NSAIDs and scavenging birds: potential impacts beyond Asia's critically endangered vultures.. Biol Lett 2007 Feb 22;3(1):90-3.
          doi: 10.1098/rsbl.2006.0554pubmed: 17443974google scholar: lookup
        46. Wibberley A, McCafferty GP, Evans C, Edwards RM, Hieble JP. Dual, but not selective, COX-1 and COX-2 inhibitors, attenuate acetic acid-evoked bladder irritation in the anaesthetised female cat.. Br J Pharmacol 2006 May;148(2):154-61.
          doi: 10.1038/sj.bjp.0706715pubmed: 16547526google scholar: lookup